BPC-157 FDA Status: What the Agency Put on the Record

BPC-157 is sold everywhere and approved nowhere. It is not an FDA-approved drug for any condition, and it is not on the list of substances a 503A compounding pharmacy may lawfully use. Under an interim policy dated October 28, 2026, HHS does not plan to pursue 503A pharmacies that compound it under strict conditions.^[7] What FDA has put on the record about it is more specific than either the marketing or the alarm around it, and the exact wording matters.

The short version: FDA reviewed BPC-157 for the compounding list, wrote down why it was concerned, and the nomination was withdrawn before it ever got on. A fresh nomination went to FDA’s advisory committee in July 2026. The committee voted for it; FDA’s reviewers had recommended against it, and no final rule has followed. An interim HHS policy dated October 28, 2026 then said HHS does not intend to take enforcement action against state-licensed pharmacies or licensed physicians that make BPC-157 acetate within a list of conditions, until a final rule decides the question.^[7] Most of what you can buy online is still labeled as a research chemical and comes from outside that system.

What FDA put on the record

FDA keeps a public list of bulk substances it judges to “present significant safety risks” in compounding.^[1] Anything that raises concerns during review lands in what the agency labels category 2. BPC-157 appears there, in the table of substances nominated but withdrawn: previously in category 2, then withdrawn by the party that nominated it.

“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information…”^[1]

— FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

Three separate concerns are packed into that. Immunogenicity means your immune system may react to the peptide itself. Peptide-related impurities are whatever else ends up in the vial alongside the intended molecule. API characterization is whether anyone can reliably establish that what is in the vial is what the label claims.

July 2026: the advisory committee voted for it, FDA has not acted

BPC-157 came back before FDA on July 23, 2026. The agency’s Pharmacy Compounding Advisory Committee took up BPC-157 free base and BPC-157 acetate as candidates for the 503A bulks list.^[4] FDA evaluated it for one use, the treatment of ulcerative colitis.^[5] FDA’s own briefing document reached a clear conclusion: “a balancing of the criteria weighs against” placing either form on the list.^[5]

The committee went the other way. Healio reported that it voted 8–6–1, twice, to put both forms on the list.^[6] FDA has not published that tally itself. Its meeting page, last updated August 6, 2026, carries the briefing documents and slides but no minutes.^[4]

A committee vote is advice, not a listing. The briefing document says FDA will not issue a final determination until the committee’s input has been considered.^[5] As of October 30, 2026, no decision on the bulks list has appeared in the Federal Register; the HHS policy described below was published there that day as a notice, not a rule, and the notice calls the policy a draft that is not binding, with written comments open for two weeks.^[8] BPC-157 is not on the 503A bulks list, and FDA’s safety-risk page still shows it in the withdrawn table.^[1]

October 28, 2026: HHS sets out enforcement discretion, under conditions

HHS then acted without a rule. Its interim policy says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds BPC-157, or five other peptides, under section 503A for as long as no final rule has settled whether each one joins the 503A bulks list, provided they meet every condition.^[7] For BPC-157 the policy names the acetate form and four routes: subcutaneous, intramuscular, oral and topical.^[7] The oral form has its own problems, covered in oral BPC-157 capsules.

• A prescription written for one specific patient.^[7]
• BPC-157 as the only active ingredient, so no blends with TB-500 or anything else.^[7]
• Raw powder made at an FDA-registered plant, with a certificate of analysis that reports identity, strength, purity and contaminant tests and names the plant that made it.^[7]
• Serious adverse event and quality reports filed through MedWatch, FDA’s reporting system, with instructions on the patient label.^[7]
• A label stating that the product is compounded and may not be resold.^[7]
• For an oral form, records showing that the formulation is adequately absorbed in humans.^[7]

HHS gives three reasons for including BPC-157: use is now documented, a lot certificate from an FDA-registered facility supplied test results FDA’s reviewers had found missing, and the conditions add lot testing, single-ingredient products and MedWatch reporting.^[7] The policy is interim, and HHS can narrow or withdraw it if safety or quality problems surface.^[7] It does not approve BPC-157, does not add it to the bulks list, and does not cover research-use-only sellers. It also leaves the safety record where FDA described it above.

What this does and does not mean

The naming problem, which is not academic

FDA has flagged something specific about how these peptides are sold: multiple salts and derivatives, with different active moieties, circulate commercially under the same common name. Two vials both saying “BPC-157” can contain chemically different substances.

That breaks the one check a careful buyer thinks they have. Comparing labels tells you nothing if the label is not a chemical identity, and a certificate of analysis is only as good as the party that produced it. In this market, that is generally the seller.

AOD-9604 sits in the same place

AOD-9604, another peptide sold for fat loss (and one that failed its own obesity trial), appears in the same withdrawn table with nearly identical language about immunogenicity, peptide-related impurities, API characterization and limited safety information. FDA adds one line it does not use for BPC-157: it “has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.”^[1]

Ipamorelin acetate, by contrast, is in the active category 2 table (503B, dated September 29, 2023), with immunogenicity and unnatural amino acids cited.^[1] KPV, another peptide sold for inflammation, sits in the same withdrawn table; we look at what the KPV evidence shows.

If you are being sold this alongside a GLP-1

Plenty of telehealth sellers list peptides beside their GLP-1 offerings, and the two are not in the same regulatory position at all. A compounded GLP-1 comes from a licensed pharmacy against a prescription, from a molecule with approved counterparts and published trials. BPC-157 has none of that, and no study has tested it in people taking a GLP-1 (what is known about the combination). TB-500, which is often sold alongside it, has its own record: what the evidence on TB-500 shows, with its doses and side effects in TB-500 side effects and dosing. For the two sold together, see BPC-157 and TB-500 blends.

1. Ask which pharmacy compounds it, and under what authority. The only cover is the HHS policy of October 28, 2026, so a seller should name a state-licensed 503A pharmacy, a single-ingredient product on a prescription for you, and a label stating that the product is compounded and may not be resold.^[7]
2. Treat “research use only” as the answer, not the disclaimer. It means no prescriber, no pharmacy and no accountability. FDA has set that label aside in its warning letters to peptide sellers, and research use only vs compounded peptides shows how a research vial differs from a compounded one.
3. Do not accept a seller’s own certificate of analysis as identity verification, given FDA’s specific point about naming.
4. Tell your prescriber. Whatever else is true, they should know what you are injecting alongside a prescribed drug. The doses used in the few human studies are listed in BPC-157 dosage in the studies.

Our register records BPC-157 on the menus of several GLP-1 sellers, which makes the first question above a practical one. Youth & Soul names ProCompounding Pharmacy and The Pharmacy Hub as its pharmacy partners, so ask which of them, if either, prepares the BPC-157, and on what basis. Always Wellness and Recovery says a licensed 503A pharmacy dispenses but does not name it, and EmbraceRX prescribes pharmacy-compounded drugs through the Samaritan MD physician network.

Others list it with no pharmacy named at all, among them Iron Med RX and TeleCareSpot. Live Vital, a physician-led practice in Utah, puts BPC-157 on a long peptide menu that also carries TB-500. Thriving Again pairs GLP-1 weight loss with testosterone and peptide care for men, and Ivy Rx lists BPC-157 beside its compounded semaglutide and tirzepatide programs. A listing tells you a seller sells it. It does not change what FDA has on the record.

Common questions